These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 8968446)

  • 1. Efficacy and safety of BMY 21,502 in Alzheimer disease.
    Shrotriya RC; Cutler NR; Sramek JJ; Veroff AE; Hironaka DY
    Ann Pharmacother; 1996 Dec; 30(12):1376-80. PubMed ID: 8968446
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The use of the Computerized Neuropsychological Test Battery (CNTB) in an efficacy and safety trial of BMY 21,502 in Alzheimer's disease.
    Cutler NR; Shrotriya RC; Sramek JJ; Veroff AE; Seifert RD; Reich LA; Hironaka DY
    Ann N Y Acad Sci; 1993 Sep; 695():332-6. PubMed ID: 8239308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial.
    Wilcock GK; Black SE; Hendrix SB; Zavitz KH; Swabb EA; Laughlin MA;
    Lancet Neurol; 2008 Jun; 7(6):483-93. PubMed ID: 18450517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial.
    Freund-Levi Y; Eriksdotter-Jönhagen M; Cederholm T; Basun H; Faxén-Irving G; Garlind A; Vedin I; Vessby B; Wahlund LO; Palmblad J
    Arch Neurol; 2006 Oct; 63(10):1402-8. PubMed ID: 17030655
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
    Weyer G; Eul A; Milde K; Wierich W; Herrmann WM
    Pharmacopsychiatry; 2000 May; 33(3):89-97. PubMed ID: 10855459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study.
    Doody RS; Gavrilova SI; Sano M; Thomas RG; Aisen PS; Bachurin SO; Seely L; Hung D;
    Lancet; 2008 Jul; 372(9634):207-15. PubMed ID: 18640457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of ABT-126 in Subjects with Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors: A Randomized, Double-Blind, Placebo-Controlled Study.
    Florian H; Meier A; Gauthier S; Lipschitz S; Lin Y; Tang Q; Othman AA; Robieson WZ; Gault LM
    J Alzheimers Dis; 2016; 51(4):1237-47. PubMed ID: 26967214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atomoxetine augmentation of cholinesterase inhibitor therapy in patients with Alzheimer disease: 6-month, randomized, double-blind, placebo-controlled, parallel-trial study.
    Mohs RC; Shiovitz TM; Tariot PN; Porsteinsson AP; Baker KD; Feldman PD
    Am J Geriatr Psychiatry; 2009 Sep; 17(9):752-9. PubMed ID: 19700948
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double-blind placebo-controlled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance, brain bioelectrical activity and cerebral perfusion.
    Alvarez XA; Mouzo R; Pichel V; Pérez P; Laredo M; Fernández-Novoa L; Corzo L; Zas R; Alcaraz M; Secades JJ; Lozano R; Cacabelos R
    Methods Find Exp Clin Pharmacol; 1999 Nov; 21(9):633-44. PubMed ID: 10669911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe.
    Feldman HH; Doody RS; Kivipelto M; Sparks DL; Waters DD; Jones RW; Schwam E; Schindler R; Hey-Hadavi J; DeMicco DA; Breazna A;
    Neurology; 2010 Mar; 74(12):956-64. PubMed ID: 20200346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebo-controlled trial.
    Seltzer B; Zolnouni P; Nunez M; Goldman R; Kumar D; Ieni J; Richardson S;
    Arch Neurol; 2004 Dec; 61(12):1852-6. PubMed ID: 15596605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AMPA potentiator treatment of cognitive deficits in Alzheimer disease.
    Chappell AS; Gonzales C; Williams J; Witte MM; Mohs RC; Sperling R
    Neurology; 2007 Mar; 68(13):1008-12. PubMed ID: 17389305
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. The Tacrine Study Group.
    Knapp MJ; Knopman DS; Solomon PR; Pendlebury WW; Davis CS; Gracon SI
    JAMA; 1994 Apr; 271(13):985-91. PubMed ID: 8139083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS; Schafer KA; Grundman M; Pfeiffer E; Sano M; Davis KL; Farlow MR; Jin S; Thomas RG; Thal LJ;
    JAMA; 2003 Jun; 289(21):2819-26. PubMed ID: 12783912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Dextromethorphan-Quinidine on Agitation in Patients With Alzheimer Disease Dementia: A Randomized Clinical Trial.
    Cummings JL; Lyketsos CG; Peskind ER; Porsteinsson AP; Mintzer JE; Scharre DW; De La Gandara JE; Agronin M; Davis CS; Nguyen U; Shin P; Tariot PN; Siffert J
    JAMA; 2015 Sep 22-29; 314(12):1242-54. PubMed ID: 26393847
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.